3 Results

Working Together to End HIV in Black Communities

Health inequities and disparities disproportionately affect Black people and other historically marginalized groups at above average rates. NIAID highlights ongoing efforts to reduce the burden of HIV among Black Americans while increasing the representation of Black communities and researchers in HIV science.

The STOMP trial evaluates an antiviral for mpox

NIAID launched the STOMP trial to determine whether the antiviral drug tecovirimat can safely and effectively treat mpox. Watch Dr. Cyrus Javan of NIAID's Division of AIDS explain the importance of the STOMP trial.

NIAID-Supported Research is Advancing the Response to Surging Syphilis Rates

Syphilis, a common sexually transmitted infection (STI) caused by the bacteria Treponema pallidum, can result in adult neurological and organ damage, as well as congenital abnormalities, stillbirths, and neonatal deaths. More research is urgently needed to diversify the diagnostic, preventive, and therapeutic options available to alter the course of the public health threat of syphilis. NIAID supports research to address these areas including studies featured at the recent STI & HIV World Congress in Chicago.


Contact the NIAID Media Team.